Press Release

April 7th, 2022

TOPADUR in collaboration with the University Hospital and University of Zurich was awarded CHF 605k by Innosuisse

Zurich-Schlieren, Switzerland, April 7th, 2022. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today announced that together with the University Hospital / University of Zurich has been awarded a 605K CHF Innosuisse grant to support proof-of-concept studies in lung fibrosis.

Pulmonary fibrosis is a chronic and usually fatal disease characterized by scarring (fibrosis) of the lung tissue resulting in a loss of respiratory function. IPF affects 3 million people worldwide, and the average survival rate of IPF patients, if untreated, is approximately 3 to 5 years from the onset of symptoms. Although few treatments are available to manage the disease, there is no cure for IPF.

In collaboration with Prof. Distler and Dr. Kania from the University Hospital and University of Zurich, the project will investigate the anti-fibrotic effects of TOP-V122. The data obtained with this grant will support TOPADUR to accelerate this unique drug candidate's development and guide the subsequent clinical developmental phases. This collaboration will use synergies between TOPADUR's expertise in drug development and the clinical and research know-how of Prof. Distler and Dr. Kania.

"We are extremely grateful for the support we have received from Innosuisse, the Swiss Innovation Agency, who awarded the grant", said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. "This project will support and extend the company's R&D activities, as we will collaborate with world-class experts at UZH to focus on developing an innovative drug candidate for the treatment of lung fibrosis", commented Dr. Naef.

About TOP-V122

TOP-V122 is a dual-mode of action phosphodiesterase type 5 inhibitor (PDE5) / organic nitrate ester that targets the cGMP-Enzyme Regulation System. In a process called `bioactivation`, TOP-V122 gets converted into nitric oxide (NO) and two more potent PDE5 inhibitors TOP-V121 and TOP-V128 in the target cells. NO activates soluble guanylyl cyclase (sGC) to synthesize cyclic guanosine-3',5'-monophosphate (cGMP), while TOP-V121 and TOP-V128 reduce the degradation of cGMP by inhibiting PDE5. TOP-V122 locally applied, locally acting compound has the potential to treat lung fibrosis by targeting fibrotic and pulmonary vascular lesions.

About TOPADUR

TOPADUR is a patient-oriented biotech company developing disruptive therapies for aging diseases. The Swiss-based biotech company developed the DualTOP™ technology platform consisting of new dual-acting drugs that increase cGMP levels to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. TOPADUR's R&D portfolio consists of promising

development candidates in regenerative medicine, oncology, ophthalmology and medical aesthetics. The DualTOP™ technology will contribute to promoting long healthy life.

For more information regarding TOPADUR PHARMA AG, please visit: www.topadur.com

Contact:
Dr. Paola Atzei
Chief Project Manager and Communications
+41 44 755 44 63
paola.atzei@topadur.com